Skip to content

D&A at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$75.6M+8.6%
Quest Diagnostics logo
Quest DiagnosticsDGX
$37M-5.1%
CareDx logo
CareDxCDNA
$3.9M+8.3%
Veracyte logo
VeracyteVCYT
$5.43M+1.3%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$419K0.0%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$2.03M+2.1%

Other financials

Income statement

See full
Revenue$696.6M+38.8%
Operating income-$93.5M-18.1%
Net income-$85.1M-27.1%
EPS (diluted)-$0.60-20.0%

Balance sheet

See full
Cash & equivalents$1.1B+11.7%
Total debt$240.1M+22.7%
Total equity$1.8B+43.1%
Total assets$2.6B+50.9%

Cash flow

See full
Operating cash flow$40.2M-9.6%
CapEx$22.1M+1.5%
Free cash flow$18.0M-20.3%

Valuation

See full
Market cap$38.88B+74.2%
Enterprise value$38.03B+76.7%
P/S15.5×+4.2×

Profitability

See full
Gross margin42.9%
Operating margin-13%+0.6pp
Net margin-14.6%+0.6pp
FCF margin4.2%-0.5pp

Returns & leverage

See full
Return on equity-29%+4.1pp
Debt / equity0.1×0.0×
Current ratio-0.9×

Where this comes from

Reported directly by Natera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Natera, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Natera, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Natera, Inc.'s D&A?
Natera, Inc. (NTRA) reported D&A of $7.1M in Q1 2026.
How has Natera, Inc.'s D&A changed year-over-year?
Natera, Inc.'s D&A increased by 2266.7% year-over-year, from $300K to $7.1M.
What is the long-term trend for Natera, Inc.'s D&A?
Over 4 years (2021 to 2025), Natera, Inc.'s D&A has grown at a 30.7% compound annual growth rate (CAGR), from $11.25M to $32.83M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.